ClinicalSerum amyloid A protein in patients with non-insulin-dependent diabetes mellitus
References (32)
- et al.
Serum amyloid A-containing human high density lipoprotein 3. Density, size and apolipoprotein composition
J Biol Chem
(1986) - et al.
Influence of serum amyloid A protein (SAA) on high density lipoprotein in chronic inflammatory disease
Clin Biochem
(1993) - et al.
Influence of serum amyloid A on cholesterol esterification in human plasma
Biochem Biophys Acta
(1989) - et al.
Association of insulin pump therapy with raised serum amyloid A in type I diabetes mellitus
Lancet
(1984) - et al.
Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure
J Lipid Res
(1982) - et al.
Insulin pump therapy and serum amyloid A
Lancet
(1984) - et al.
Circulating acute phase reactive proteins as indications of infection in poorly controlled diabetes mellitus
Diabetes Res Clin Pract
(1988) Increased levels of acute-phase serum proteins in diabetics
Metabolism
(1989)- et al.
Apolipoprotein A-I and apolipoprotein SAA half-lives during acute inflammation and amyloidogenesis
Biochim Biophys Acta
(1990) - et al.
Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey
Lancet
(1988)
Serum amyloid A, an acute phase protein, inhibits platelet activation
J Lab Clin Med
Metabolism of serum amyloid A proteins (SAA) in high density lipoproteins and chylomicrons of non-human primates (Vervet monkey)
Am J Pathol
Effect of purified protein SAA on immune response in vitro: Mechanisms of suppression
J Immunol
SAA suppression of immune response in vitro: Evidence for an effect on T cell-macrophage interaction
J Immunol
Interactions of bacterial lipopolysaccharide with acute-phase rabbit serum and isolation of two forms of rabbit serum amyloid A
J Immunol
Continuous subcutaneous insulin infusion does not induce a significant acute phase response of serum amyloid A protein
Diabetologia
Cited by (41)
Serum amyloid A concentrations, COVID-19 severity and mortality: An updated systematic review and meta-analysis
2021, International Journal of Infectious DiseasesGlycation of HDL blunts its anti-inflammatory and cholesterol efflux capacities in vitro, but has no effect in poorly controlled type 1 diabetes subjects
2020, Journal of Diabetes and its ComplicationsAcute phase reactant serum amyloid A in inflammation and other diseases
2019, Advances in Clinical ChemistryCitation Excerpt :Most studies suggest that A-SAA putatively influences the pathogenesis of type 2 diabetes mellitus (T2DM). The A-SAA levels in plasma from patients with type 2 diabetes were significantly higher than those from healthy individuals [167]. Moreover, a significant positive correlation was observed between the A-SAA plasma levels and the development of type 2 diabetes.
Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease
2016, Journal of Diabetes and its ComplicationsSerum amyloid A and inflammation in diabetic kidney disease and podocytes
2015, Laboratory InvestigationSerum amyloid A and C-reactive protein levels may predict microalbuminuria and macroalbuminuria in newly diagnosed type 1 diabetic patients
2013, Journal of Diabetes and its ComplicationsCitation Excerpt :A cross-sectional study by Kumon et al. detected a significantly higher level of SAA in type 2 diabetic patients compared to healthy subjects and additionally an association between SAA levels and urinary albumin excretion was observed (Kumon et al., 1994). SAA is an acute phase protein synthesized in the liver and secreted into the blood with a 1000 fold elevation following inflammation (Kumon et al., 1994). Transforming growth factor-β (TGF-β) is a cytokine that stimulates acute phase proteins synthesis (Mackiewicz et al., 1990), and has been found over expressed in glomeruli of patients with diabetic nephropathy and is involved in the induction of extracellular matrix production (Yamamoto et al., 1993).